April 28, 2020 07:20 AM EDTUpdated 10:26 AM

Covid-19 roundup: Researchers claim trial success for Roche's Actemra as Alexion jumps in; Pfizer gambling $500M on an ambitious campaign

Amber Tong

Senior Editor

John Carroll

Editor & Founder

After Regeneron announced a setback on Monday with its research on the use of Kevzara in fighting the pandemic, hopes for the anti-inflammatory IL-6 class …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Researchers claim trial success for Roche's Actemra as Alexion jumps in; Pfizer gambling $500M on an ambitious campaign

Amber Tong

Senior Editor

John Carroll

Editor & Founder

Sign up to read this article for free.

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Covid-19 roundup: Re­searchers claim tri­al suc­cess for Roche's Actem­ra as Alex­ion jumps in; Pfiz­er gam­bling $500M on an am­bi­tious cam­paign

Senior Editor

Editor & Founder

Sign up to read this article for free.

Covid-19 roundup: Researchers claim trial success for Roche's Actemra as Alexion jumps in; Pfizer gambling $500M on an ambitious campaign